Table 2.
Descriptive statistics for nominal variables for the total study population (N = 275)
| Variable | F | % |
| Gender | ||
| Men | 95 | 34.5 |
| Women | 180 | 65.5 |
| Age > 55 years | ||
| Yes | 173 | 62.9 |
| No | 102 | 37.1 |
| Ro stage of lung disease | ||
| 0 | 68 | 24.7 |
| 1 | 148 | 53.8 |
| 2 | 47 | 17.1 |
| 3 | 12 | 4.3 |
| Course of the sarcoidosis | ||
| Acute | 102 | 27.1 |
| Chronic | 173 | 62.9 |
| Extrapulmonary sarcoidosis | ||
| Yes | 191 | 69.5 |
| No | 84 | 30.5 |
| Treatment | ||
| No treatment | 17 | 6.2 |
| Prednisone | 98 | 35.6 |
| Methotrexate | 146 | 53.1 |
| Chloroquine | 5 | 1.8 |
| Prednisone + Methotrexate | 9 | 3.3 |
| Smoking status | ||
| Active smoker | 25 | 9.1 |
| Non-smoker | 204 | 74.2 |
| Ex-smoker | 46 | 16.8 |
| Total FAS score ≥ 22 | ||
| Yes | 172 | 62.5 |
| No | 103 | 37.5 |
F = frequency; FAS = Fatigue Assessment Scale.